<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="19/05/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10208867" creator="Yo Shidahara">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>10208867</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Protein_molecule" id="T1" lex="Angiotensin_II">Angiotensin II</term> activates the <term sem="Protein_family_or_group" id="T2" lex="proinflammatory_transcription_factor">proinflammatory transcription factor</term> <term sem="Protein_complex" id="T3" lex="nuclear_factor-kappaB">nuclear factor-kappaB</term> in <term sem="Cell_natural" id="T4" lex="human_monocyte">human monocytes</term>.</sentence>
<event id="E1">
<type class="Positive_regulation" />
<theme idref="T3" />
<cause idref="T1" />
<clue>Angiotensin II <clueType>activates</clueType> the proinflammatory transcription factor nuclear factor-kappaB <clueLoc>in human monocytes</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The <term sem="Other" id="T5" lex="renin-angiotensin_system"><term sem="Protein_molecule" id="T6" lex="renin">renin</term>-<term sem="Peptide" id="T7" lex="angiotensin">angiotensin</term> system</term> may contribute to the pathogenesis of <term sem="Other" id="T8" lex="atherosclerosis">atherosclerosis</term>.</sentence>
<event id="E2">
<type />
<theme idref="T8" />
<cause idref="T8" />
<clue>The renin-angiotensin system may contribute to the <clueType>pathogenesis</clueType> <linkCause>of</linkCause> atherosclerosis.</clue>
<comment>SOO</comment>
</event>
<event uncertainty="probable" id="E3">
<type class="Correlation" />
<theme idref="T5" />
<theme idref="E2" />
<clue>The renin-angiotensin system may <clueType>contribute</clueType> <linkTheme>to</linkTheme> the pathogenesis of atherosclerosis.</clue>
</event>
<sentence id="S3">A common feature of all stages of <term sem="Other" id="T9" lex="atherosclerosis">atherosclerosis</term> is <term sem="Other" id="T10" lex="inflammation">inflammation</term> of the <term sem="Tissue_natural" id="T11" lex="vessel_wall">vessel wall</term>.</sentence>
<sentence id="S4">The transcription factor <term sem="Protein_complex" id="T12" lex="nuclear_factor-kappaB">nuclear factor-kappaB</term> (<term sem="Protein_complex" id="T13" lex="NF-kappaB">NF-kappaB</term>) participates in most <term sem="Other" id="T14" lex="signaling_pathway">signaling pathways</term> involved in <term sem="Other" id="T15" lex="inflammation">inflammation</term>.</sentence>
<event id="E4">
<type class="Positive_regulation" />
<theme idref="T15" />
<cause idref="T14" />
<clue>The transcription factor nuclear factor-kappaB (NF-kappaB) participates in most signaling pathways <clueType>involved</clueType> <linkTheme>in</linkTheme> inflammation.</clue>
</event>
<event id="E5">
<type class="Positive_regulation" />
<theme idref="E4" />
<cause idref="T13" />
<clue>The transcription factor nuclear factor-kappaB (NF-kappaB) <clueType>participates</clueType> <linkTheme>in</linkTheme> most signaling pathways involved in inflammation.</clue>
</event>
<sentence id="S5">This study therefore examined the effect of <term sem="Protein_molecule" id="T16" lex="angiotensin_(ANG)_II">angiotensin (ANG) II</term> on <term sem="Other" id="T17" lex="NF-kappaB_activation"><term sem="Protein_complex" id="T18" lex="NF-kappaB">NF-kappaB</term> activation</term> in <term sem="Cell_natural" id="T19" lex="monocytic_cell">monocytic cells</term>, a major cellular component of <term sem="Tissue_natural" id="T20" lex="human_atheroma">human atheroma</term>, by <term sem="Other" id="T21" lex="electrophoretic_mobility_shift_assay">electrophoretic mobility shift assay</term>.</sentence>
<event id="E6">
<type class="Positive_regulation" />
<theme idref="T18" />
<clue>This study therefore examined the effect of angiotensin (ANG) II on NF-kappaB <clueType>activation</clueType> in monocytic cells, a major cellular component of human atheroma, by electrophoretic mobility shift assay.</clue>
</event>
<event uncertainty="doubtful" id="E7">
<type class="Regulation" />
<theme idref="E6" />
<cause idref="T16" />
<clue>This study therefore examined the <clueType>effect</clueType> <linkCause>of</linkCause> angiotensin (ANG) II <linkTheme>on</linkTheme> NF-kappaB activation in monocytic cells, a major cellular component of human atheroma, <clueExperiment>by electrophoretic mobility shift assay</clueExperiment>.</clue>
</event>
<sentence id="S6"><term sem="Protein_molecule" id="T22" lex="ANG_II">ANG II</term>, like <term sem="Protein_molecule" id="T23" lex="TNFalpha">TNFalpha</term>, caused rapid activation of <term sem="Protein_molecule" id="T24" lex="NF-kappaB">NF-kappaB</term> in <term sem="Cell_natural" id="T25" lex="human_mononuclear_cell">human mononuclear cells</term> isolated from <term sem="Tissue_natural" id="T26" lex="peripheral_blood">peripheral blood</term> by <term sem="Other" id="T27" lex="Ficoll_density_gradient">Ficoll density gradient</term>.</sentence>
<event id="E8">
<type class="Positive_regulation" />
<theme idref="T24" />
<cause idref="T22" />
<clue>ANG II, like TNFalpha, <clueType>caused</clueType> rapid <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappaB <clueLoc>in human mononuclear cells isolated from peripheral blood by Ficoll density gradient</clueLoc>.</clue>
</event>
<event id="E9">
<type class="Positive_regulation" />
<theme idref="T24" />
<cause idref="T23" />
<clue>ANG II, like TNFalpha, <clueType>caused</clueType> rapid <clueType>activation</clueType> <linkTheme>of</linkTheme> NF-kappaB <clueLoc>in human mononuclear cells isolated from peripheral blood by Ficoll density gradient</clueLoc>.</clue>
</event>
<sentence id="S7">This <term sem="Other" id="T28" lex="ANG_II_effect"><term sem="Protein_molecule" id="T29" lex="ANG_II">ANG II</term> effect</term> was blocked by the <term sem="Organic_compound_other" id="T30" lex="angiotensin_AT1_receptor_antagonist">angiotensin AT1 receptor antagonist</term> <term sem="Organic_compound_other" id="T31" lex="losartan">losartan</term>.</sentence>
<event id="E10">
<type class="Negative_regulation" />
<theme idref="E8" />
<cause idref="T31" />
<clue><corefTheme>This ANG II effect</corefTheme> was <clueType>blocked</clueType> <linkCause>by</linkCause> the angiotensin AT1 receptor antagonist losartan.</clue>
</event>
<sentence id="S8">Specificity of <term sem="Protein_molecule" id="T32" lex="ANG_II">ANG II</term>-induced <term sem="Other" id="T33" lex="NF-kappaB_activation"><term sem="Protein_complex" id="T34" lex="NF-kappaB">NF-kappaB</term> activation</term> was ascertained by <cons sem="(AND Other Other)" id="T35" lex="(AND supershift_experiment competition_experiment)"><frag id="F1">supershift</frag> and <frag id="F2">competition</frag> <frag id="F3">experiments</frag></cons>.</sentence>
<event id="E11">
<type class="Positive_regulation" />
<theme idref="T34" />
<clue>Specificity of ANG II-induced NF-kappaB <clueType>activation</clueType> was ascertained by supershift and competition experiments.</clue>
</event>
<event id="E12">
<type class="Positive_regulation" />
<theme idref="E11" />
<cause idref="T33" />
<clue>Specificity of ANG II-<linkCause>induced</linkCause> NF-kappaB activation was ascertained <clueExperiment>by supershift and competition experiments</clueExperiment>.</clue>
</event>
<sentence id="S9">Moreover, <term sem="Protein_molecule" id="T36" lex="ANG_II">ANG II</term> stimulated <term sem="Other" id="T37" lex="NF-kappaB_activation"><term sem="Protein_complex" id="T38" lex="NF-kappaB">NF-kappaB</term> activation</term> in <term sem="Cell_natural" id="T39" lex="human_monocyte">human monocytes</term>, but not in <term sem="Cell_natural" id="T40" lex="lymphocyte">lymphocytes</term> from the same preparation.</sentence>
<event id="E13">
<type class="Positive_regulation" />
<theme idref="T38" />
<clue>Moreover, ANG II stimulated NF-kappaB <clueType>activation</clueType> in human monocytes, but not in lymphocytes from the same preparation.</clue>
</event>
<event id="E14">
<type class="Positive_regulation" />
<theme idref="E13" />
<cause idref="T36" />
<clue>Moreover, ANG II <clueType>stimulated</clueType> NF-kappaB activation <clueLoc>in human monocytes</clueLoc>, but not in lymphocytes from the same preparation.</clue>
</event>
<event assertion="non-exist" id="E15">
<type class="Positive_regulation" />
<theme idref="E13" />
<cause idref="T36" />
<clue>Moreover, ANG II <clueType>stimulated</clueType> NF-kappaB activation in human monocytes, but not <clueLoc>in lymphocytes from the same preparation</clueLoc>.</clue>
</event>
<sentence id="S10">Together, the data demonstrate the ability of the <term sem="Peptide" id="T41" lex="vasoactive_peptide">vasoactive peptide</term> <term sem="Protein_molecule" id="T42" lex="ANG_II">ANG II</term> to activate <term sem="Other" id="T43" lex="inflammatory_pathway">inflammatory pathways</term> in <term sem="Cell_natural" id="T44" lex="human_monocyte">human monocytes</term>.</sentence>
<event id="E16">
<type class="Positive_regulation" />
<theme idref="T43" />
<cause idref="T42" />
<clue>Together, the data demonstrate the ability of the vasoactive peptide ANG II to <clueType>activate</clueType> inflammatory pathways <clueLoc>in human monocytes</clueLoc>.</clue>
</event>
<sentence id="S11">Copyright 1999 Academic Press.</sentence>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
